FIGS, Inc. (FIGS) Earnings Call Transcript & Summary

August 6, 2026

New York Stock Exchange US Consumer Discretionary Textiles, Apparel and Luxury Goods earnings 67 min

Earnings Call Speaker Segments

Tom Shaw

executive
#1

Good afternoon, and thanks for being here as we go over FIGS's results for the second quarter of 2026, which came out this afternoon and are available in our earnings press release as well as the shareholder presentation on our investor relations site at ir.wearfigs.com. With us on the call today are Trina Spear, our Co-founder and Chief Executive Officer, and Sarah Oughtred, our Chief Financial Officer. Just a reminder that anything said on this call that isn't about past events counts as forward-looking statements. That can cover predictions, expectations, or estimates, including those regarding future financial performance, market opportunity, or business plans. Statements about the future come with risk and uncertainty, and what actually happens may be materially different; those and other risks appear in our SEC filings, among them the 10-Q we filed today. You shouldn't lean too heavily on any forward-looking statement, since each one reflects only today's view and we have no duty to revise it later. Also, we'll be going over some non-GAAP metrics and key performance indicators, which in our view serve as helpful supplemental measures for grasping how our business is doing. You can find definitions of these non-GAAP measures, along with reconciliations to the closest comparable GAAP measures, in our shareholder presentation. With that, I'd like to hand the call over to Trina.

Trina Spear

executive
#2

Appreciate that, Tom. Good afternoon, everybody, and thanks for being with us today. During Q2, FIGS carried forward the strong, wide-ranging momentum we've been seeing, which speaks to how sustainable our success is and to the genuinely distinctive position we hold. Net revenues rose 29%, reaching $197 million, which came in above our outlook and made it the third quarter in a row of growth at 25% or better. Worth noting: not since 2021 have we put together such a robust, extended run of growth. The really thrilling part is that this growth originates throughout the business instead of from a single area; we're experiencing fantastic traction everywhere, across our channels, product categories, geographies, and customer cohorts, setting multiple records for the brand. To illustrate, Q2 was our biggest quarter ever for scrub wear sales, and each of our three market expansion opportunities, international teams, and community hubs reached new peaks. The metrics make our strength clear. Active customers climbed 13%, hitting 3.1 million. AOV set a record of its own at $127, and how often customers purchase kept rising. That potent mix pushed net revenues per active customer to a brand all-time high of $229, exceeding even the $227 peak from our COVID period. This accomplishment reflects all that we've described over recent quarters and leaves us with still stronger conviction about the growth possibilities ahead. Equally striking is what we achieved on profitability. Setting aside the prior year portion of tariff refunds, adjusted EBITDA margin jumped to 18.6%. Behind that result, greater full price selling and better returns — both telling signs of brand health — along with overall expense leverage made possible by our extraordinary top-line momentum, powered our strong margin expansion. Last, not only did we step up our share buyback activity in the quarter, we have also just declared a fresh $100 million authorization, which shows how much faith we have in our brand, our strategy, and the opportunity ahead. Given that strength, let me pause to restate why we think we're winning, since I believe it's essential background for all that comes next. It begins with brand differentiation. For us, technically advanced products are a must, and we're broadening our premium positioning while adding still more impact and relevance to our product range, from scrubs through the entire layering system, to address the needs of healthcare professionals. What genuinely distinguishes FIGS is our singular capacity to create connection and take part in healthcare's cultural conversation in a manner nobody else can. Product plus storytelling — that pairing is extraordinarily powerful and difficult to copy. Next, we're establishing a lasting foundation for growth, underpinned by ongoing investment in our team, technology, and customer acquisition; we've discussed at length how much more sophisticated we've become in how we bring the brand and product to life, work intended to do more than fuel results in any one year. What they're focused on is creating the durability and nimbleness needed to keep producing strong results in revenue, earnings, and returns for shareholders over the long term. Number three, the sector we operate in is the finest one globally. Health care reaches every person. Those requirements keep expanding since the pressures of the job are intensified by an older demographic and an increased emphasis on well-being. Over the coming 10 years, health care and social assistance is expected to see the biggest employment gains and rank as the quickest-expanding sector. Our data reflects that demand. The wider health care sector is acting as a strong engine of total employment growth in the United States, with an average of more than 50,000 positions being added to the field every month during this year. These broad macro forces, together with the solid underpinnings of medical apparel, render this sector extremely appealing. In contrast to other clothing makers, the items we offer aren't based on trends and don't create inventory exposure. What we sell are non-discretionary, replenishment-based uniforms that never fall out of fashion and that medical professionals require throughout the entire year. Since a large number of them are employed in tightly crowded facilities wearing FIGS as a mobile advertisement, we gain from a word-of-mouth effect that is truly one of a kind. Before I continue, I'd like to give a brief status update regarding our supply chain. I referenced resilience earlier in my comments; that term fits here as well. A Withhold Release Order was just issued by U.S. Customs and Border Protection, and it is presently stopping us from bringing product into the United States from our partner in Jordan. Having dealt with COVID and Middle East turmoil, dealing with supply chain difficulties isn't something new for us; we've consistently managed to get through them thanks to how robust and adaptable the supply chain we've established is. That's still the case right now. Our team is working across functions to adjust our planning so we can reduce disruption during the back half of the year. This involves using capacity from our other established, reliable partners and speeding up their output. As a reminder, our footprint of high volume and low SKU count is a strong point of differentiation that makes us very appealing to the top suppliers globally. Most significantly, despite this obstacle, we can increase our revenue and profit objectives; not only have we flowed through the benefit from our Q2 results, we've additionally incorporated higher projections for the rest of the year. This is precisely the type of nimbleness that highlights how strong the foundation we've constructed is. It sets us up for long-term execution in providing excellent products to our community. Let me walk through some of the developments we're most thrilled about in product, brand, and market expansion. Beginning with product, we're succeeding where style, color, fabric, and fit come together. On style, we're advancing the range of options for medical professionals, building on our hit core styles with contemporary designs that merge utility, aesthetics, and ease. Our scrub pants illustrate this well. Broader leg options keep drawing a strong response. We keep adding fresh items in this category, such as new waistband choices launching during the current quarter. Our approach shows the distinctive merchandising engine we have working; we release limited edition variants that create buzz and fast sales while also sparking more curiosity about the core lines that make up most of what we do. At FIGS, color has always mattered. It's part of our brand's DNA in both core and limited edition designs. We constantly take in feedback, study trends, and act fast. Espresso illustrates this well. Saying our community was eager for that shade would be putting it mildly. We listened to them. We came back with 2 distinct launch moments during this year, among them a product drop as recently as last week that went fast. We've leveraged color to connect with cultural moments, bringing it into our Star Wars collaboration in Q2, and into our fresh collaboration with Marvel's Spider-Man, which arrived this quarter alongside the movie's debut, and became a massive success. When it comes to fabrication, we stay committed to serving every kind of use case, pairing our signature FIONx with FORMx, and now our latest FiberX. FORMx keeps connecting with people and expanding as an addition to what we primarily offer, and we're really thrilled to continue developing the FiberX narrative over the coming weeks. Tying all of this together is fit.

Trina Spear

executive
#3

Every one of our new offerings lines up with the fit initiatives we've been pushing for several years now, and we keep feeling good about the improvements showing up via reduced returns and encouraging customer responses; when it comes to non-scrub wear, our attention stays on expanding our layering system. This is an area where we're succeeding. A 40% increase during the quarter marked our strongest in almost 4 years. Non-scrub wear accounts for close to 20% of our business at this point, and we think its share can climb further down the road as we develop important segments, such as under scrubs, lab coats, outerwear, footwear, medical grade compression socks, and jewelry. Even though healthcare professionals might wear a uniform, they still want ways to personalize and accessorize their appearance. That leads me to something we're beyond thrilled to share. You might have noticed from our latest social posts that we have acquired V Coterie. A partner of ours for a long time on pins, V Coterie offers a wide array of pins, jewelry, charms, and accessories aimed at the healthcare community. These aren't just ordinary accessories. V Coterie's founder, Lynna Van Mierlo, whom we're delighted to share is now with FIGS, is a former dentist and a remarkable entrepreneur who has uniquely blended jewelry and healthcare in a manner nobody else has. Although V Coterie is immaterial when it comes to the purchase itself, our community adores these items, and we think this puts us in position to unlock significant growth possibilities within this category moving forward. In the end, this stands as a strong illustration of how we capture a larger share of wallet and boost consideration for our brand. Regarding the brand, we experienced several impactful moments over the quarter, and what I most want to emphasize is how we're weaving our backing of this community through numerous efforts in genuine, meaningful ways. Beginning with Nurses Week, we're pleased with our financial results, even though the real highlight was how we authentically captured the lived experience of nurses. This initiative shed light on the many difficulties they confront daily at work, while simultaneously honoring their steadfast dedication to always prioritizing their patients, which will never change; that initiative then extended onward powerfully 2 weeks afterward when we responded to those exact difficulties at our Healthcare Is Human rally in Washington, D.C. I gave a preview of our intentions on the previous call, and the event itself exceeded what we anticipated. It was our largest advocacy push so far; with hundreds of wonderful people at the rally, over 30 meetings with important members of Congress, and triple-digit increases across key social metrics. Together, we advanced 3 vital priorities. Passing the FIGS-created Healthcare is Human Act, the first ever federal tax credit aimed specifically at healthcare professionals. Funding the Dr. Lorna Breen Act to deliver mental health services designed specifically for healthcare professionals. We're putting forward the Speak Free Act, which safeguards the ability of healthcare professionals to voice concerns when safety issues arise for them or those they treat. Noah Wyle stood with us once more, and my pride in how this community turned out and acted together couldn't be greater. Then we pushed these initiatives further by bringing back our FIGS Retreat in June. Close to 80 healthcare professionals joined us, and we built an environment for them to rest and recover, look after themselves, bond over common experiences, and refocus on their top priorities; this embodies our mission and the way we support our community, and we're prioritizing these key moments moving ahead. That brand energy has continued into Q3. A string of excellent product launches has already happened, among them our Spider-Man collaboration, Espresso's comeback, and V Coterie's introduction on our platform. Yesterday, we launched our back-to-school push featuring the newest installment of Never Change, which shines a light on the lifelong learning path as seen by residents. Now for market expansion, all three of our growth drivers posted record net revenues. International grew 67%, and more than 50 points of that came from our established comp markets. Today we serve 85 international markets, with 27 added so far this year. Since we're getting more efficient across the board, we're boosting what we put into building our international brand. We're discovering additional approaches to localize and bring in-person events to life, such as our inaugural Nurses Week gathering in Toronto. We're at the very start of enlisting ambassadors and backing user-generated content in key markets where it carries exceptional weight. We're scaling up on new search and social platforms, among them LINE in Japan, Kakao in South Korea, and Douyin in China, all extremely pertinent digital channels for speeding up local reach and impact. Regarding our teams business, momentum keeps building as we concentrate on deepening ties with current institutions, expanding our pipeline of prospective accounts, and delivering on our technology roadmap. For instance, we just brought on Bupa Dental Care, a division of the British United Provident Association, one of the biggest private healthcare and insurance firms globally. Our first efforts there will center on equipping their close to 400 dental centers throughout the U.K., showing the kind of reach and impact this channel can achieve, at home and overseas. Backing those efforts on the technology front, we keep enhancing our platform's functionality in Q2. More work lies ahead on our roadmap, and it's all built with one aim: making it as simple as possible to outfit a wide variety of healthcare workforces in FIGS and deliver unmatched value in that experience. Community hubs likewise turned in record results, thanks to both solid comp store performance and contributions from new stores. Our store-level focus stays on refining the assortment, going further into core colors and styles to match the larger share of new customers arriving through the channel. As we think about what's next, the team has locked in 4 new leases for sites we intend to open in the latter part of this year. Those include Fashion Square in Scottsdale, Tysons Corner outside of Washington, D.C., Valley Fair near San Jose, and Aventura Mall in Miami, and every one of them draws on robust local healthcare communities. Work is already underway on finding spots for 2027 and past that. There's no way we could be more thrilled about the direction this channel is headed. Before passing things to Sarah, there's a final point I consider significant that explains why my confidence is so high. Previously, I've discussed the metrics I regard as the leading indicators revealing where we stand as a brand: search, website traffic, social followers, and more. Once those metrics inflected last year, we felt we were beginning to turn the corner, and that is precisely what unfolded over the quarters that followed, with powerful momentum throughout our business. What gives me encouragement is that these leading indicators keep expanding, forming a tremendous pipeline for engagement down the road. Throughout the whole brand funnel, from awareness to consideration to preference, we're witnessing improvement year-to-date. Our brand is increasingly breaking through at a moment when plenty of others in the industry are merely treading water.

Trina Spear

executive
#4

In the end, we think we're set up to grow our industry leadership and transform things for healthcare professionals in a way nobody else is able to, exactly as we've done over 14 years. For the short term, we see that through a solid view on both revenue and earnings; over the long term, we recognize we're only beginning, since there's so much more opportunity and so much impact still available to us throughout the healthcare community; with that, I'll hand things to Sarah to go over our financial results and full-year outlook.

Sarah Oughtred

executive
#5

Appreciate that, Trina. Looking at every part of it, Q2 came in exceptionally strong, carrying momentum from an excellent first quarter with gains everywhere, and that sets us up for a better back half than the guidance we'd previously implied. What FIGS is doing is creating a robust ecosystem serving the whole healthcare community, and it goes far past mere transactions; that community, in turn, plays a key role in sending insights back to the brand, which we think makes for a truly distinctive story within the wider consumer landscape. I'll begin by walking through our remarkable second quarter, which delivered several notable records and multi-year peaks that Trina already highlighted. Next, I'll walk you through the higher full-year outlook we've issued, covering how we presently see tariffs affecting us and why we're confident about meeting the stronger second-half targets we've set. Turning to the results: net revenues for Q2 rose 29% compared with the same quarter last year, reaching $196.6 million, which beat the guidance we'd given for growth in the low 20% range. Across our categories, geographies, and channels, essentially every area of the business is expanding at a solid clip. During the quarter we ran launch events and promotions that delivered very strong results, and we remain hugely optimistic about our performance on ordinary selling days that don't involve dedicated brand activations. Our active customer base expanded at a faster pace once more, climbing 13% compared to the same period last year and landing at 3.1 million, with notable momentum coming from shoppers who are returning to us. The typical order size rose 9%, hitting $127, primarily because average unit retail moved higher following pricing steps taken early in 2026, and it also got a lift from better-quality sales thanks to reduced markdowns and fewer returns. On top of those forces, buying frequency is trending upward as well. Taken together, these elements pushed our trailing 12-month figure for net revenues per active customer up 10%, setting a FIGS record of $229. Looking at category performance, scrub wear was up 27% and accounted for 82% of net revenues during the period. The performance we're seeing across the board keeps pleasing us, with robust gains from both our core franchises and limited edition lines. Color especially made a big difference, and better sequencing plus newness helped core productivity as well. Non-scrub wear jumped 40% and accounted for 18% of net revenues. The growth spanned many areas, led by under scrubs, where our assortment improved across styles and fabrications, and outerwear, which came from extending core product families. We're set to bring even more excitement and differentiation to both of those areas in the quarters ahead. Accessories represent another emerging opportunity, with strength showing up in varied areas like hair accessories, our bags assortment, and compression socks. We're thrilled about the opportunity to drive more growth, especially with the V Coterie jewelry line now fully in the mix — it's already proven to be a strong performer for us. When you look at how everything fits together — color, our tech-forward scrub wear, the broader head-to-toe range, and compelling storytelling — it all forms a potent ecosystem that gives FIGS a genuine edge in the market. Breaking it down by region, U.S. Net revenues climbed 22% to $158.7 million, while international net revenues jumped 67% to $37.9 million. On the U.S. side, I'd like to reinforce a few of the leading indicators Trina called out, because they were both major contributors to our Q2 results and positive signs for what's coming. Search and traffic improvements represent a promising start. On top of that, we're seeing extra retention driven by ongoing gains in our social audience, email registrations, and interaction metrics; we also noticed positive indicators across both first-time and repeat buyers. People coming to us for the first time continue to show up with strong value and hold onto it down the line. The power of our repeat purchasers is evident in frequent buying and movement into larger spending tiers. Our overseas expansion continues to reflect a sound balance of new and returning shoppers. In Q2, this meant impressive gains across Europe, Latin America, and Mexico, along with considerably better results in Canada, Australia, and the Middle East. Now shifting to margins, let me start with a few details regarding tariff refunds. On our last earnings call, we mentioned taking steps to get back about $20.5 million that had been paid out under the IEEPA tariff. Since we received $4.5 million of that during Q2, we concluded it was likely the rest would come through, so we included the full benefit in our GAAP results. The effect was a $15.4 million reduction in cost of goods sold, which relates to tariffs we had expensed starting when the IEEPA tariffs kicked in back in February 2025 — $7.9 million of that was expensed in fiscal 2025, and $7.5 million was expensed in the first half of fiscal 2026. On top of that, we took a write-down of roughly $5.1 million against the value at which our inventory was carried, related to tariffs we had previously capitalized; as those products are eventually sold, that amount will run through the P&L. We have since received the full refund during Q3, and we expect it to show up in cash together with our upcoming results. Later in my remarks, I'll walk through each of these impacts on our results and our outlook in greater depth. Turning to Q2 gross margin, it rose 820 basis points to 75.2%. Included in that number is the 780 basis point cumulative impact from the $15.4 million tariff refund. This underlying improvement, once refunds are excluded, was mainly fueled by favorable effects from pricing and continuing efficiency initiatives, such as product costing, along with better than anticipated results from more full price selling and reduced return rates. Those gains exceeded the effect of higher non-IEEPA tariffs. Our selling expense during Q2 came to $43.7 million, which equals 22.2% of net revenues, versus 22.6% a year earlier. The reduced expense rate stemmed from advantageous outbound shipping rates and net revenue leverage. Partly countering those efficiencies, we felt the effect of supply chain investments and international mix. Marketing expense during Q2 totaled $28.5 million, equal to 14.5% of net revenues, a decline from 15.2% a year earlier. After entering Q2 with a higher marketing rate planned for Q1, what we saw in the quarter was net revenue leverage at work along with efficiencies in digital CAC. Beyond that, we keep making opportunistic investments throughout the company, such as international brand awareness efforts, our FIGS Retreat activations, and broader brand partnerships. Q2 G&A came to $40.4 million, which equals 20.5% of net revenues, versus 22.8% a year ago. That reduced G&A rate stemmed mainly from net revenue leverage and a decrease in stock-based compensation expense, partly offset by what we put into our team. With the tariff refund benefit included, operating margin in Q2 reached 17.9%, up against 6.5% a year earlier. For the quarter, we recorded net income of $28.4 million, which works out to $0.15 per diluted share. A year earlier, net income stood at $7.1 million, or $0.04 per diluted share. When figuring adjusted EBITDA for this period, we excluded a $7.9 million gain stemming from IEEPA tariff refunds associated with goods sold during fiscal 2025. As a result, our adjusted EBITDA margin came to 18.6%, while in the comparable period last year it was 12.9%. It's true that Q2 adjusted EBITDA does include the benefit from that portion of the tariff refund linked to goods sold in the year-to-date period, and that contributed to our stronger performance. Even so, this approach is consistent with how our forward-looking results will be handled as the inventory in question is sold.

Sarah Oughtred

executive
#6

Looking at our balance sheet, we closed out the quarter with net cash equivalents plus short-term investments totaling $296.3 million. Inventory came down 12% versus the same period last year, landing at $119.6 million, and that figure includes the $5.1 million inventory adjustment tied to IEEPA. Beyond those items, we keep pushing for more efficiency in this area, balancing strategic purchasing against a more proactive approach to managing inventory. For Q3, we anticipate inventory will still be down double digits compared with a year ago because of the supplier transitions we're making, yet we remain confident about hitting our stronger top-line outlook. When it comes to capital allocation, share repurchases made during the quarter through our ongoing repurchase program came to roughly $24 million, at a weighted average price of $11.94 per share. Cumulatively, we've now bought back approximately $81 million since the program began nearly two years ago. On top of that, our board of directors approved another $100 million increase to the ongoing share repurchase program, which lifts our total share repurchase capacity to $119 million. Lastly, capital expenditures for the quarter reached $2.6 million, still reflecting software capitalization and leasehold improvements, with bigger community hub-related outlays still on the schedule for later in the year. Now to our updated outlook. For full year 2026, net revenues are now projected to grow roughly 20%, ahead of the 14%-16% growth we previously guided. That reflects both the stronger momentum from the first half and raised expectations for the back half of the year. Within this outlook, we're planning for Q3 net revenue growth of about 20% year-over-year and Q4 net revenue growth of about 10% year-over-year. This factors in the comparison against improving performance as we progress through the second half of fiscal 2025, including the 33% growth acceleration we achieved last Q4. Moving to gross margin, we now anticipate full-year GAAP gross margin of approximately 69.5%, which includes the tariff refund from the quarter and the expected benefit as impacted goods in inventory get sold during the second half of the year. The underlying gross margin expectation hasn't changed from our prior guide, which had called for modest full-year improvement year-over-year from 66.5% in fiscal 2025. On the favorable side, we see both our Q2 operating performance and the modest improvement relative to what we previously expected, given the Section 301 tariffs that took effect as of July 24th. This new rate assumption of 12.5% compares with our earlier global tariff assumption of 15%, though because of average costing and shipment timing, the benefit for the fiscal year is minimal. Largely offsetting those positives, we intend to use air freight to speed up certain products. It's important to remind you about the gross margin comparisons in the back half of the year. We still expect a year-over-year decline in Q3, followed by a large year-over-year improvement in Q4. While our Q4 gross margin rate is planned to be the lowest of the year, it is still expected to remain well above the prior year, in part due to the large inventory write-off comparison. Moving on to SG&A, we anticipate that improved net revenue leverage will be the biggest driver in general, helping Q3 more than Q4. In our view, that translates into expense leverage throughout selling, marketing, and G&A during the third quarter, but solely on the marketing line in the fourth quarter. On the whole, we've raised our outlook for full-year operating margin from a range of 7.8% to 8% up to roughly 10.8%, including refunds. We've likewise lifted our full-year adjusted EBITDA margin outlook from 13% to 13.2% up to 14.8% to 15%, including refunds tied to our first half performance and sell-through expectations in the second half. That incorporates an anticipated Q3 adjusted EBITDA margin of about 14%, an increase from the 12.4% level a year earlier. To sum up, the FIGS brand is connecting more strongly than ever, and we're capitalizing on this opportunity extremely well amid a dynamic operating environment. Our guidance for net revenue growth is almost twice our initial outlook, while our profitability keeps inflecting. We think this shows our brand's rising resonance, our team's remarkable execution, and the distinctive opportunity before us to keep redefining expectations alongside the healthcare community. We're ready now to take your questions. Operator?

Bob Drbul

analyst
#7

Hello there. Wishing you a good afternoon, and well done on yet one more impressive outcome.

Trina Spear

executive
#8

Thank you, Bob. I appreciate that.

Bob Drbul

analyst
#9

Got it. I suppose the thing I'd most like to begin with is this: whenever you examine how new buyers are growing, plus how repeat buyers are growing, could you walk us through what you believe is currently clicking so effectively on the customer front?

Trina Spear

executive
#10

Absolutely. My sense is it traces back to the pair of guiding stars for us — namely product and marketing. We've kept on providing the finest merchandise that satisfies each requirement a healthcare professional has. That happens from head to toe throughout our layering system; we've kept on achieving consistent enhancements to our fit, to our function, delivering comfort, durability, and style to our community. On the second element, which I'm aware you're familiar with, Bob, it concerns marketing. We keep on launching amazing campaigns that genuinely strike a chord and frequently go viral inside our community. You've witnessed that across the year via our Never Change campaign this year. My belief is that's pulling new buyers toward the brand. What's lovely about our operation, I'd say, is that a great deal remains powered by word of mouth. Each FIGS customer functions as a moving billboard who brings in that subsequent customer for us. That genuinely is a distinctive dynamic considering the densely populated settings where healthcare professionals carry out their work; as for the repeat customer element, this is an industry propelled by replenishment. Healthcare professionals require their uniforms in order to head to work and perform their duties. They return again and again for their Catarina top and Isabel wide-leg pants, correct? They return for their under scrubs and their scrub jackets and their compression socks and sort of all these various items and various components of their uniform that they require in order to go and perform their job. Seeing the quarter's results has been thrilling, yet we genuinely sense that we're only at the beginning. There's more to mention, but certainly we're energized by what we're observing in the business and what we'll keep on executing.

Bob Drbul

analyst
#11

Excellent. Thanks a lot. Best of luck.

Brian Nagel

analyst
#12

Hello there. I'd also like to offer my congrats on what was a spectacular quarter. Well done.

Sarah Oughtred

executive
#13

Thanks.

Trina Spear

executive
#14

Thank you, Brian.

Brian Nagel

analyst
#15

I’d like to build somewhat on what Bob Drbul asked, but when we examine the customer growth and, really, total sales here, previously you mentioned lapsed customers, and perhaps that was an area of weakness. Now it appears to be an area of strength. What are you seeing among that customer base? People who might have bought from FIGS in the past, then stopped, are they returning at this point? Is that turning into a meaningful incremental driver?

Sarah Oughtred

executive
#16

We are genuinely fueling customer growth through multiple elements. Growth in customers comes from new buyers; it comes from those lapsed customers who are returning, and also simply from how often our returning customers purchase. Each of those three has truly been delivering for us for a number of quarters now. When we examine those lapsed customers, they are returning at a solid pace. That has stayed fairly consistent for us. We believe we are offering the correct product assortment, the correct chance for them to keep coming back and stay involved with the brand. We expect that future growth will keep arriving through all of those elements.

Brian Nagel

analyst
#17

That's useful, Sarah. For my second question, I wanted to touch on the tariff refund. A growing number of consumer businesses have begun bringing up this subject, and obviously it provided a lift — we observed that at least in what Gap reported. What I'm trying to get at is whether, from a strategic standpoint, getting these refunds alters your thinking about how you operate over the next few quarters?

Sarah Oughtred

executive
#18

Yes. We received $20.5 million back. Our cash position is extremely strong. We haven't designated it toward any particular purpose. Everything we do on a daily basis centers on making life better for healthcare workers and coming up with answers to the challenges they face. We'll keep doing exactly what we've been doing — putting money back into the company to advance that mission. At the same time, we'll keep providing returns to our shareholders. You'd have noticed that through our buyback activity. For us, I don't believe this shifts anything. It simply allows us to keep putting that cash to work very efficiently so we can generate growth going forward.

Brian Nagel

analyst
#19

Thank you, and congrats again.

Sarah Oughtred

executive
#20

Thanks, Brian.

Trina Spear

executive
#21

Thank you, Brian.

Brooke Roach

analyst
#22

Good afternoon, and thanks for letting us ask. Trina, I'd love to hear more about how you're strategically growing the business, since you pursued this move into V Coterie and jewelry. As you aim to serve every part of how a healthcare professional dresses, what does that mean for your category and your TAM?

Trina Spear

executive
#23

Brooke, thank you so much for asking. The acquisition of V Coterie has us incredibly excited. V Coterie's founder is a remarkable entrepreneur, Lena, and she's now with FIGS. She leads pins, charms, and jewelry for us, and we've been acquainted with her for a long while. Heather and I have known Lena for, I'd say, more than 7 years. She was a FIGS ambassador, in fact, and she also created this amazing company. As you mentioned, the whole point is to assist healthcare professionals in making their uniforms their own, and it says something about who they are and what they do; beyond that, charms, jewelry, and pins are deeply personal, and that forges a very strong emotional bond between our community and us; our goal is to help healthcare professionals mark occasions such as finishing nursing school, getting certifications, or working in an ICU. This is a truly thrilling development that will help us deepen emotional loyalty with our community even further. As you noted, I've long said that lazy companies sell into TAM, while innovative companies create TAM, and here we have a TAM creation opportunity; we are inventing TAM, since this really wasn't part of the industry, correct? Jewelry, charms, and pins like these belong to a huge industry that wasn't part of ours. Bringing that in and making it enjoyable and cool has been truly exciting. Just in month one, the response we're seeing is very strong. Several key styles throughout our assortment have already sold out. We're working quickly to restock them. Overall, I'd say healthcare is difficult, and as you're aware, Brooke, we deliver the fun, which matters so much, and that's what we'll keep doing as we keep strengthening this bond with our community.

Brooke Roach

analyst
#24

Sarah, maybe a brief follow-up question for you. Given that you're now guiding adjusted EBITDA margins to about 15%, is that something you see as a new floor to grow from as you head into 2027, especially since you'll be cycling past some of those tariff refunds while also facing higher raw material and oil costs?

Sarah Oughtred

executive
#25

Yes. I'd say, just to put that 15% in context, it does capture the gain from tariffs that had been expensed during Q1 and Q2. You have to take that gain into account. And on the other side, we are bringing in some extra air freight. I'd say this gives us a pretty solid foundation to keep growing from in the years ahead. There are plenty of pluses and minuses at play, but that 15% figure is also how we'd present our results going forward.

Brooke Roach

analyst
#26

Great, thank you. I'll hand it off.

Matt Koranda

analyst
#27

Nice work, everyone. I suppose I'll ask about AOVs. They rose considerably in the second quarter. I just wanted to know if you might break down a few of the factors behind that, particularly on pricing. Are shoppers putting more in their carts, or is the mix improving because of the outerwear range and certain items with higher ASPs?

Sarah Oughtred

executive
#28

Hello, Matt. AOVs for the quarter were up 9%, which matches the growth we recorded in Q1. A good share of that comes from the pricing actions we implemented in Q1. Beyond that, we're also getting the upside of reduced markdowns and better return rates. It's honestly been encouraging to watch. Yes, the way that's moving is something we feel good about. Right now it may not be showing up in UPT, though that was something we anticipated, simply because AURs are higher due to pricing. All the same, those results are still better than what we initially projected back when we implemented pricing, and I'm genuinely pleased that, as I noted, additional elements beyond pricing are fueling that stronger-quality expansion in our AOV.

Matt Koranda

analyst
#29

All right, that's useful. Looking ahead, what assumptions about active customers are built into the sales growth guidance? The reason I ask is that engagement has been really robust over the past 2 quarters, and my assumption is you'd factor that in, but how should we frame the split between existing customers engaging more and new customers when it comes to what drives growth for the balance of the year?

Sarah Oughtred

executive
#30

Sure. Yeah. Like I mentioned earlier, total revenue growth stems from more active customers, more orders per customer, and higher net AOV. For the remainder of the year, we'd anticipate active customer growth staying at a solid pace; AOV should also keep rising, since much of that really comes from pricing; that holds through the rest of the year until it laps in Q1 of 2027. The piece I'd point to is orders per customer, where frequency has been really healthy. We aren't budgeting for that same level of frequency improvement, though it could be an upside if customers keep engaging the way they have been.

Trina Spear

executive
#31

Let me just add this: the interval from one purchase to the next is shrinking, correct? Customers are returning to us at a higher rate, which stems from our products and our brands, and it also comes from the industry settling back into a normal pattern, right? In that pattern, people require their uniforms, and those in our healthcare community require their uniforms again and again. We are witnessing genuine wins everywhere, in new customers, in repeat customers, in AOV. No single factor is really what's fueling these wins.

Matt Koranda

analyst
#32

Awesome to hear. Thanks, Trina. Thanks, Sarah.

Sarah Oughtred

executive
#33

Thanks.

Rick Patel

analyst
#34

Thanks. Afternoon, everyone, and congratulations on those impressive numbers. I was wondering if you might give us more detail regarding the rise in frequency. Has the main factor been shoppers returning to purchase something from the essential lineup, such as the basic scrubs, or are they instead moving into the neighboring product lines? Since what you sell keeps growing, with fresh scrub materials and a broader selection beyond scrubs, I would really like to grasp what mainly fuels that frequency, plus how you see it playing out ahead, especially the areas where you feel most confident.

Trina Spear

executive
#35

Yes, absolutely. In my view, the way repeat purchasing works is exactly why this sector is so appealing. What we have achieved, I believe, is delivering not only what those in healthcare require, but additionally what they desire; that truly powers the restocking-based nature of our model. Once we moved past the COVID situation we've talked about, that simply sped things up, and frequency sped up too. You can observe it in our scrub wear, which rose 27% during the quarter. You can observe it as well in non-scrub wear, which climbed 40% during the quarter. Consider the path, or the progression, of someone working in healthcare: they tend to start with the essential scrubs, after that perhaps they pick up an under scrub, after that they restock their scrub wear once more. They give a limited edition style drop a try, after that they return and purchase an outer wear item, say. After that perhaps they return and pick up their preferred Catarina top alongside the Isabel pant in one new color or 2 new colors, depending on the most recent drop. The more you return to the brand, following your 2nd, 3rd, 4th, 5th purchase, you in fact wind up purchasing still more as time passes and purchasing more non-scrub wear as time passes. That is the remarkable thing about our business; that is what makes FIGS beautiful: we aren't spending money to bring people back. The more they return to us, the more loyal they become. Our task is to keep pushing that forward and assist them in becoming increasingly engaged with the brand. We are insanely fixated on healthcare professionals, and they are equally fixated on us; we will keep up that conversation, tell their stories, introduce new products, fuel engagement, and turn them into a FIGS lover for life.

Rick Patel

analyst
#36

Could you also discuss how you plan to approach promotions during the second half? With the robust demand you're experiencing on regular business days, do you believe there's an opportunity to reduce markdowns, or would you consider last year's schedule a reliable guide for this year?

Sarah Oughtred

executive
#37

That's something we keep an eye on at all times. We keep witnessing the strong performance on our typical business days, and that does provide us with the room to scale back on promotions when it's appropriate. I believe at this point, our approach mirrors a comparable rhythm to what we had last year. Like I mentioned, we stay flexible, we stay quick to adapt, and we keep watching the shopper along with which actions we should take. Right now, we'll set our plans based on the promotional activities we ran in 2H of last year; this covers our back to school event that's taking place at this moment; we've always put on an exciting Black Friday, Cyber Monday. Those usual promotions will remain part of what we do.

Rick Patel

analyst
#38

Great. Thanks very much.

Sarah Oughtred

executive
#39

Thank you.

Dana Telsey

analyst
#40

Hello. Nice work, all of you, on those amazing numbers; wonderful to witness. Trina, when you consider the activation and engagement side — be it that Spider-Man film or, I believe, the Emmys talk slot from last year — what's your thinking looking ahead? Do you have fresh activations in the pipeline? In what way does that tie back to product? On your site, I notice a few of the accessories plus some of the jewelry listed there as well. Might we expect even more of that non-scrub wear down the road, and what effect does it have on margins? And finally, Sarah, regarding Jordan and the situation with sourcing product and freight costs, what's your view on how product arrives? Does some other region take Jordan's place, or how does that factor into receiving goods? Thanks.

Trina Spear

executive
#41

Thanks, Dana. Yes, watching so many of these collaborations and activations truly connect with our community has been amazing. You really notice it with our ongoing partnership with Star Wars. We launched a newer collaboration with Owala. That one was a smash. I believe we sold out in, I don't know, under a single day. Spider-Man, which happens to be the top Marvel franchise — something I hadn't even realized. It's so fantastic; it genuinely surpassed even what I expected it would achieve. Fresh ideas are always with us. Our team is the best; this world-class group of ours constantly scans around and spots what truly fits our brand, what genuinely resonates with our community, and what will make people incredibly thrilled. V Coterie, as you mentioned, stands as another great illustration of hearing our community and providing what they're after, exceeding what they anticipate, and again, delivering the enjoyment. Our creative team is simply the finest, forever thinking in unconventional ways. Truly eager about what's ahead in the back half of the year, and what's ahead in 2027, 2028. Ideas never dry up for us. I'll hand things to Sarah for the remaining questions.

Sarah Oughtred

executive
#42

Yes. It's true that non-scrub wear comes with a smaller margin. At present, that category still represents less than 20% of what we do, which means we can take that hit; we've communicated that when we look at margins over a longer horizon, growth in our profit probably isn't going to come from gross margins, simply because of the mix shift taking place. We believe we can more than make up for it by using the chances we have with SG&A to keep growing that profit margin in future years. Offering non-scrub wear is an excellent method for us to keep delivering a complete wardrobe to the healthcare professional. We're pleased with how it helps us connect with that customer, keeps driving the top line, and genuinely strengthens where we stand. We're capable of handling the entire economic picture in later years.

Dana Telsey

analyst
#43

Thanks.

Adrienne Yih

analyst
#44

Hi there, good afternoon. Let me add my congrats as well. It's genuinely great to witness this sort of pickup and turning point. Speaking of which, that marks 3 straight quarters above 20%, with revenue up 25%. You have the healthcare professional advantage working in your favor, you have growth in active customers, and you have RevPAC rising by double digits. Perhaps I'll phrase it another way. What's the reason we shouldn't view this as a fresh plateau of double-digit growth on the top line? And could you discuss certain marketing efforts you've undertaken or did previously to ramp up during Q4 and Q1? What kind of marketing does that involve? Is it about brand awareness? Are we observing a halo effect, that delayed impact, coming through and genuinely beginning to connect? Thanks.

Trina Spear

executive
#45

Yes; regarding marketing, I believe we're truly centered on brand awareness and helping a larger portion of this community learn who we are, since the moment someone discovers FIGS, they adore FIGS; so I think that's a genuinely fascinating dynamic, correct? We have 3.1 million active customers. There are 140 million healthcare professionals globally, so our overall market share remains fairly small. So we're genuinely concentrated on those top-of-funnel campaigns; that's what you've observed, I'd say, across the last few years now, in helping more and more individuals discover us and adore us. We move them from awareness to consideration, to conversion, so we'll keep doing that. Sarah, would you like to address that first part?

Sarah Oughtred

executive
#46

Sure, we haven't provided guidance for 2027; clearly, we're exiting Q4 with a 10% exit rate. All year long, we've kept seeing genuinely robust metrics, broadly based across every one of our drivers. That keeps giving us a fair amount of conviction that substantial growth still lies in front of us, and that our strategy and our team are capable of carrying on delivering it. In 2025, we achieved 16% growth. For 2026, we're now guiding to 20% growth. We see momentum carrying forward with everything we've been building this year. More chances for our growth drivers to account for a bigger share of that growth in 2027 and beyond.

Adrienne Yih

analyst
#47

Great. Could you provide some kind of comparison for brand awareness — what you have now, say, against 12 months back? And then Trina, here's a question about ranking, more or less, for you. When you look ahead 3 to 5 years, there's comp growth, correct? That's from those 3.1 active customers you already have. Then you have lots of other paths that aren't comp growth — international, non-scrub wear, teams, rolling out retail stores. Could you roughly rank, from nearer term out to longer term, where the drivers sit for that extra layer of growth? Thanks.

Sarah Oughtred

executive
#48

Regarding how aware people are of our brand, we've recorded gains of several points so far this year across every metric — our unaided awareness, our awareness, our consideration, product mix — and much of the credit goes to the fantastic job the brand team is doing telling people about us, with truly great storytelling that resonates strongly with healthcare professionals. Those trends make us quite happy. At the levels we currently sit at, we believe there's clearly room to keep lifting each of them; our strategy is the right one to keep pursuing that.

Trina Spear

executive
#49

When I think about what lies ahead over the coming 3 to 5 years, and what gets me the most fired up, ranking all my babies is nearly impossible. But forced to choose, I'd point to international as the top driver, and the figures back that up. Right? It rose 67% during the quarter. The chance we see across every one of these markets is simply amazing, yet watching Mexico do what it's doing, watching the EU, watching LatAm, watching Canada and Australia come roaring back, that's just incredibly thrilling. We're genuinely constructing something for the long haul abroad, exactly the way we built things in the U.S., and it's paying off. Next, if you asked me, I'm truly enthusiastic about our hubs. We've got just 5 stores. Consider a few of the biggest brands that stood where we stand, the Nikes and Lululemons out there, and I never enjoy putting us side by side with anyone, but at our size, accomplishing what we're accomplishing, basically nearly all through digital means with merely 5 stores, that has never happened before. The opportunity before us is enormous. We've barely begun. We just discussed the 4 opening in the back half of this year. That's tremendously exciting. They're delivering results; they're beating what we'd projected. We've picked up so many lessons, and now we intend to push much harder. Last, teams. Watching major organizations, such as Bupa, such as European Wax Center, approach FIGS and declare, "We're prepared to commit hundreds of thousands, millions of dollars with you all to equip our teams and make our workforce more professional and standardized." That's genuinely thrilling as well. Were I forced to rank them, that's the order I'd choose, every one at an early stage, every one still nascent regarding what they'll mean for our business, every one tremendously exciting as we look toward what's ahead.

Adrienne Yih

analyst
#50

That's wonderful to hear. Wishing you the best, and great job.

Trina Spear

executive
#51

Thanks.

Ashley Owens

analyst
#52

Excellent. I really appreciate it, and congratulations from me too.

Trina Spear

executive
#53

Thanks.

Ashley Owens

analyst
#54

Perhaps we could begin by examining Jordan, since historically it has generated a substantial portion of your output, so I'm just attempting to gauge a few details here. First off, I suppose, what quantity of weeks or months' worth of the Jordan Source core product is currently stored at your U.S. distribution center? And next, what would be the practical timeframe for completely supplying that volume to additional nations like Vietnam? How sure are you that you're able to maintain inventory of those core styles to meet some of the robust demand patterns you've been witnessing?

Trina Spear

executive
#55

Certainly. Pardon me, could you please repeat that question once more? The audio dropped for a moment.

Ashley Owens

analyst
#56

Oh, right, my apologies; first off, what's the supply in the U.S. for the Jordan Source core product — how many weeks or months? And second, when will you have that volume fully resourced, plus how confident are you about keeping core styles available to meet the demand you've been seeing?

Trina Spear

executive
#57

Yeah. No, I'd say that's a great question. I'd say the difficulty we ran into here isn't something new for us. During COVID and the Middle East disruption, we dealt with a broad set of obstacles. The real point here is the resilience and adaptability of the supply chain we've spent 14 years building, and that's what allows us to keep performing well regardless of circumstances. When it comes to mitigation — that is, keeping our core styles available — we genuinely collaborated across functions and made adjustments in order to reduce the impact of this WRO. That involves leveraging capacity among many of our other reliable partners, where we're accelerating their output so that our requirements are fulfilled. We're well positioned to manage this, since we had already been reducing risk on particular products and launches because of the Middle East conflict, which was reflected in the changes we reported last quarter. I'd say our position is solid, and we've taken care of the bulk of the problem. Just to remind everyone — I believe I've mentioned this before — manufacturers would love to have us as a customer. Ours is a business with enormous volume but very few SKUs. Because replenishment drives what we do, we're able to be an outstanding partner for the companies that make our products. That advantage is showing up in results right now, isn't it? It lets us stay nimble, make quick moves, and secure the capacity required to serve our community's needs. One more thing, since it matters a great deal: despite all of this, we are still lifting our guidance for both revenue and earnings; what we're doing isn't merely carrying Q2's numbers forward. On top of all that, we're adding still higher guidance. Let me be clear: absent this issue, our situation would be even stronger. We have strong conviction that we'll deliver on both the back half and the entire year at levels exceeding what we shared with you a quarter ago.

Ashley Owens

analyst
#58

Got it. Perhaps I'll just add one more thing on that. Since you're doing some air shipping, does that air freight expense basically cancel out the entire tariff gain you're expecting, or do you have assumptions built in that this continues into the back half? And maybe one final item, just to squeeze in a question about the Bupa Dental Care win for Teams. From your perspective, does this indicate Teams is beginning to reach an inflection point? I'd be interested to know what the ramp and reorder pattern would look like for a customer of that size. Thanks.

Sarah Oughtred

executive
#59

The clearest way I can lay this out is by comparing our updated adjusted EBITDA guidance against the prior one. We're capturing the refund tied to the first half, and in the second half we're capturing the share of refunds that sat in inventory and will come through in that period; that represents more than 100 basis points of gain there. We're letting the Q2 benefit flow through. We've lifted the back half of the year, and we're passing that along. There's a partial offset from air freight, plus a chance to put that flow-through back into the business for areas where we believe we can keep fueling growth; we are certainly passing it through, and we keep reinvesting in the business. Lots of pluses and minuses, and we are flowing it through.

Nathan Feather

analyst
#60

Hey, everyone. I appreciate you taking my question, and congratulations to you too. These results are truly outstanding. I'd like to explore a bit further the approach to marketing internationally that you're implementing. I'm curious to know, given how quickly that side of the business has scaled, as you aim to boost the total dollar increases there, how do you weigh the trade-off between broader worldwide promotion and receiving the brand glow from the U.S. versus establishing recognition and subsequently cultivating interest in specific countries? Are you adding more staff to region-specific groups so you can accomplish that more successfully? Thank you.

Trina Spear

executive
#61

Hello, Nathan. I really appreciate the question. I believe it ties back to our approach of going broad and going deep, and that approach is succeeding. Just to remind you, in the markets where we go deep—Canada, Australia, U.K., and Mexico—we're executing marketing across the entire funnel, correct? We're genuinely adapting our brand to suit that market and truly delivering enjoyable and captivating events to these places. Those campaigns and the recognition they generate are sparking curiosity about our brand, and they're also producing significant efficiency in the lower funnel. It's wonderful to witness; when it comes to going broad, which involves a bigger count of nations, clearly, we're experimenting, correct? Our primary emphasis is really on the lower funnel. We're expanding our ambassador network in these places, and that approach is succeeding. Once those markets grow in size, they gain the privilege, so to speak, of joining our go deep approach, where we put additional funds behind it. What I'd say we've discovered somewhat is somewhat in these, what we'll refer to as high potential markets. China, Japan, South Korea, France, Germany. In these markets we're observing, and we're putting money into more upper funnel activity to generate that brand recognition because we're noticing the effect. They're receiving more of that promotion, and we're adapting as they grow. It's truly remarkable to witness how these upper funnel initiatives and our narrative and our creativity, which is genuinely our special ingredient, correct? It's the reason we share such a bond with our community across the globe, how that's functioning at a regional level worldwide. As we keep moving forward here, we'll keep carrying out this plan. We're turning a profit in nearly every market where we operate, we're truly seeing these initiatives deliver results.

Nathan Feather

analyst
#62

That's really useful, thanks.

Trina Spear

executive
#63

Thanks a lot. One interesting thing I'd like to mention: searches for FIGS have now surpassed searches for scrubs. That's how you can tell you're on the path to owning a category, the way Kleenex does, the way Band-Aid does, the way Jacuzzi does. That's the direction we're going. We'll keep delivering at the very highest level. Thanks so much for being with us.

Operator

operator
#64

This concludes today's call. Thank you for attending. You may now disconnect.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete FIGS, Inc. transcript — plus 131,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to FIGS, Inc. earnings transcripts and 131,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in FIGS, Inc. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.